Carcinoma espumoso de la próstata

Llarena Ibarguren, Roberto; Lecumberri Castaños, David; Padilla Nieva, Jesús; Crespo Atín, Víctor; Martín Bazaco, Jesús; Azurmendi Sastre, Víctor; Eizaguirre Zarza, Beatriz; Pertusa Peña, Carlos.
Arch. esp. urol. (Ed. impr.) ; 56(7): 833-835, sept. 2003.
Artículo en Es | IBECS (España) | ID: ibc-25453

Documentos relacionados

  1. Association of high-grade prostatic intraepithelial neoplasia immunohistochemical profile with acinar adenocarcinoma of the prostate.
  2. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma.
  3. Prostate cancer genetic alterations in Hispanic men.
  4. Definitive local therapy for T4 prostate cancer associated with improved local control and survival.
  5. Treatment-related Neuroendocrine Prostate Carcinoma-Diagnostic and Molecular Correlates.
  6. Treatment strategies and drug resistance mechanisms in adenocarcinoma of different organs.
  7. Expression pattern and prognostic value of key regulators for N7-methylguanosine RNA modification in prostate cancer.
  8. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
  9. Interobserver reproducibility of cribriform cancer in prostate needle biopsies and validation of International Society of Urological Pathology criteria.
  10. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.